# NOEVIR RAYSELA - zinc oxide, octinoxate, titanium dioxide cream NOEVIR USA INC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

-----

#### **Drug Facts**

#### **Drug Facts**

Drug Facts
Active Ingredients
ZINC OXIDE 14.25%
OCTINOXATE 7.5%
TITANIUM DIOXIDE 2.07%
Sunscreen
Sunscreen

#### Uses

- Helps prevent sunburn.
- Higher SPF gives more sunburn protection.
- Provides high protection against sunburn.

#### Warnings

For external use only.

When using this product

• Keep out of eyes. Rinse with water to remove.

#### Stop use and ask a doctor if

• Rash or irritation develops and lasts.

#### Keep out of reach of children

• If swallowed, get medical help or contact a Poison Control Center right away.

#### Directions

- Apply evenly before sun exposure.
- Children under 6 months of age ask a doctor.
- Reapply as needed or after towel drying, swimming or sweating.

#### Other Information

#### Sun Alert

Limiting sun exposure, wearing protective clothing and using sunscreens may reduce the risks of skin aging, skin cancer, and other harmful effects of the sun.

## **■RAYSELA FACE PROTECTOR UV**



NOEVIR GINZA TOKYO

NET. WT. 1.2 OZ. - 35g

NOEVIR RAYSELA
FACE PROTECTOR UV
SPF 30+ PA++
Active Ingredients
DNC ORDIC 14:2%
OTHERWAY
THENAUM DICKICE 2:2%
Uses
sinkings prevent sunburn, protection, surpovides high protection against sunburn.
Higher 5°F pless more sunburn protection, surpovides high protection against sunburn.
Higher 5°F pless more sunburn protection, surpovides the protection against sunburn.
Higher 5°F pless more sunburn protection, surpovides the pless more sunburn.
Higher 5°F pless more sunburn protection, surpovides the pless more sunburn.
Higher 5°F pless more sunburn protection, and surpovides the protection and surpovides the protection of the surpovides the pless of the pless of

## **■RAYSELA FACE PROTECTOR UV**

NOEVIR RAYSELA			
FACE PROTECTOR UV SPF 30+ PA+++  Drug Facts  Active Ingredients Purpose ZINC CKIDE 14.28% Suscreen OCTINGANTE 7.5% Suscreen TITANIUM DIOXIDE 2.07% Suscreen	Drug Facts (continued) Inactive Ingredients were, concensusowe, sostnum, sortewoort, surtuse arrow, osemeore, rece		
Uses  If Helps prevent surburn.  If Higher SPF gives more surburn protection.  Provides high protection egainst surburn.  Warrnings For external use only.  When using this product  Kleep out of eyes. Rinse with water to remove.  Stop use and set a doctor if a Rash or infrastion develops and lasts.  Keep out of reach of children  If swallowed, get medical help or contact a Poison Control Center right sway.	DIMETRICAN, FIGO- DOCUMENT ALL BUSINESS, OVER- DOCUMENT ALL BUSINESS, OVER- DOCUMENT ALL BUSINESS, OVER- DOCUMENT ALL BUSINESS, OVER- DIMETRICAN, BUSINESS, OVER- BUSINESS, STANDA, BUSINESS, ALL BUSINESS, OVER- DESIGNATION, BUSINESS, OVER- BUSINESS, OVER- BUSINESS, OVER- BUSINESS, BUSINESS, ALL BUSIN	RAYSELA  FACE PROTECTOR UV Protection UV Visage  SPF 30+ PA+++	
Directions  Apply evenly before sun exposure.  Children under 8 months of age: ask a doctor.  Basephy as needed or after towel drying, eximming or sweeting.  Other information  Sun Alert: Limiting our exposure, wearing protective ciching and using sunscreens may reduce the risks of skin aging, skin cancer, and other harmful effects of the sun.	DOMETHICOMENTHOUSE COPCLINES, SOUM DELOPES, DOMETHICOMENNIN DOMETHICOMENNIN DOMETHICOMENNIN DOMETHICOMENNIN DOMETHICOMENNIN DOMETHICOMENNIN STOTAL MODIFICATION NOTIFICATION N	NOEVIR GINZA TOKYO NET. WT. 1.2 OZ 35g	JANH-F 8096 494502286215c
	_		_

### **NOEVIR RAYSELA**

zinc oxide, octinoxate, titanium dioxide cream

Product Information				
Product Type	HUMAN OTC DRUG	Item Code (Source)	NDC:62908-011	
Route of Administration	TOPICAL			

Active Ingredient/Active Moiety			
Ingredient Name	<b>Basis of Strength</b>	Strength	
ZINC OXIDE (UNII: SOI2LOH54Z) (ZINC OXIDE - UNII:SOI2LOH54Z)	ZINC OXIDE	14250 mg in 100 g	
OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51)	OCTINOXATE	7500 mg in 100 g	
TITANIUM DIO XIDE (UNII: 15FIX9 V2JP) (TITANIUM DIO XIDE - UNII:15FIX9 V2JP)	TITANIUM DIO XIDE	2070 mg in 100 g	

P	Packaging			
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:62908-011-02	1 in 1 BOX		
1	NDC:62908-011-01	35 g in 1 TUBE		

Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
unapproved drug other		0 1/0 1/20 10		

## Labeler - NOEVIR USA INC (018593293)

## Registrant - NO EVIR USA INC (018593293)

Establishment			
Name	Address	ID/FEI	Business Operations
NOEVIR USA INC		018593293	manufacture

Revised: 11/2009 NOEVIR USA INC